Randy Schreckhise

CEO & Co-founder
Randy has made contributions to a number of approved therapeutics and therapeutic candidates through finance, business development, operations and strategy roles at aTyr Pharma, Abilita Bio, Trius Therapeutics, Ardea Biosciences, Human Genome Sciences and ZymoGenetics, and also through work in project management, protein biochemistry and genetics during his eight years at ZymoGenetics. Earlier in his career he worked in the Basic Sciences and Clinical Divisions at The Fred Hutchinson Cancer Research Center, where he studied meiotic recombination of the fission yeast S. pombe and also developed DNA-based assays for the detection of invasive fungal disease. For the past eight years, Randy has been an active member of The San Diego Entrepreneurs Exchange, and currently serves as a Board Member. He received an MBA with a concentration in finance from Seattle University and a BS in microbiology with a minor in molecular biology from Washington State University, where he was a Howard Hughes Undergraduate Research Fellow.

Mark Sullivan, MD, MPH

Dr. Mark Sullivan holds undergraduate degrees in microbiology and molecular biology through Washington State University and advanced degrees of Doctor of Medicine and Master of Public Health both through the University of Washington. He is a board certified physician in three specialties of Internal Medicine, Critical Care Medicine, and Occupational/Environmental Medicine with special interest in toxic exposure assessment and treatment. Dr. Sullivan completed his MPH research thesis on the association between transition metal components of < 2.5 micron particulate matter (PM 2.5) and lung function and density as potentially relates to chronic obstructive pulmonary disease (COPD) prevalence. Past research experience includes identifying the structure of the working genome of the Human Foamy Retrovirus at Fred Hutchinson Cancer Research Center, and helping to identify the Alzheimer’s and Werner’s disease gene locus at the University of Washington.

David Giegel, PhD

Chief Scientific Officer & SAB Chair
Dr. Giegel brings more than twenty-five years of expertise in drug discovery and development to August Therapeutics. He most recently served as President and Chief Scientific Officer of TissueNetix, Inc., a company he founded. Prior to TissueNetix, Dr. Giegel was President and Chief Scientific Officer of MicroStem. Previously, he was an Adjunct Associate Research Professor at San Diego State University, and was Entrepreneur-in-Residence at CONNECT, San Diego, where he mentored companies in the Springboard Program. Dr. Giegel also was Senior Director of the Molecular Sciences Group at Celgene, and held scientific leadership positions at MitoKor, Pfizer, and Warner-Lambert/Parke-Davis. He earned his Ph.D. in Biological Chemistry from the University of Michigan and a B.S. in Chemistry from Miami University in Ohio.